GSK (GSK) Stock Forecast & Price Target

$49.06 -0.25 (-0.50%)

Closing price 03:59 PM Eastern

Extended Trading

$49.40 +0.34 (+0.70%)

As of 05:13 PM Eastern

Compare

GSK - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Reduce

Based on 10 Analyst Ratings

Sell
3

Hold
5

Buy
2

Based on 10 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 10 analysts, 3 have given a sell rating, 5 have given a hold rating, and 2 have given a buy rating for GSK.

Consensus Price Target

$53.00
8.02% Upside

According to the 10 analysts' twelve-month price targets for GSK, the average price target is $53.00. The highest price target for GSK is $53.00, while the lowest price target for GSK is $53.00. The average price target represents a forecasted upside of 8.02% from the current price of $49.06.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GSK Analyst Ratings Over Time

Type	Current Forecast 6/2/25 to 6/2/26	1 Month Ago 5/3/25 to 5/3/26	3 Months Ago 3/4/25 to 3/4/26	1 Year Ago 6/2/24 to 6/2/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	3 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	0 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)	7 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$53.00	$53.00	$44.13	$37.38
Forecasted Upside	8.02% Upside	2.62% Upside	-22.45% Downside	-10.21% Downside
Consensus Rating	Reduce	Reduce	Reduce	Hold

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Medical Companies	Broader Market
Consensus Rating Score	1.90	2.30	2.52
Consensus Rating	Reduce	Hold	Moderate Buy
Predicted Upside	8.63% Upside	1,731.48% Upside	15.47% Upside
News Sentiment Rating	Neutral News See Recent GSK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/1/2026	Weiss Ratings Not Rated		Upgrade	Hold (C+) ➝ Buy (B)
2/20/2026	Barclays 3 of 5 stars	James Gordon Not Rated	Reiterated Rating	Underweight
2/9/2026	Citigroup 4 of 5 stars		Reiterated Rating	Hold ➝ Neutral
2/9/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
1/16/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
1/14/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Underweight
12/10/2025	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Reduce
11/25/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Underperform ➝ Neutral
10/30/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Wan Nurhayati Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$53.00	+13.21%
10/27/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Leuchten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold ➝ Buy
The cat is out the bag (Ad) Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. Watch Porter Stansberry's full investigation into the Final Displacement now
6/3/2025	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/15/2025	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Verdult Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral	$35.25	-1.07%
10/31/2024	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seamus Fernandez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/7/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jasper Hellweg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2024	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A. Hauber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:30 PM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, May 28, 2026. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

The current stock price is around $51.65, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
GSK plc has a solid dividend payout ratio of approximately 38.8%, indicating that the company is generating sufficient earnings to cover its dividend payments, which can provide a steady income stream for investors.
The company reported a significant increase in revenue, with a year-over-year growth of 6.2%, showcasing its ability to expand and perform well in the market.
GSK plc has a strong return on equity of 45.90%, reflecting effective management and the ability to generate profits from shareholders' investments.
Recent updates on their HIV pipeline indicate a focused approach to portfolio management, which could lead to future growth and innovation in their product offerings.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

GSK plc has decreased its dividend payment by an average of 0.1% annually over the last three years, which may concern income-focused investors looking for consistent returns.
The company has a relatively high debt-to-equity ratio of 0.92, suggesting that it relies on debt financing, which can be risky in volatile market conditions.
Despite recent revenue growth, the company faces intense competition in the pharmaceutical industry, which could impact its market share and profitability.
The stock has shown volatility, with a fifty-two week low of $35.45 and a high of $61.69, indicating potential risks for investors regarding price stability.
Analysts have forecasted a slight decline in earnings per share for the current year, which may signal challenges ahead for the company's profitability.

GSK Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is $53.00, with a high forecast of $53.00 and a low forecast of $53.00.

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 3 sell ratings, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" GSK shares.

According to analysts, GSK's stock has a predicted upside of 8.02% based on their 12-month stock forecasts.

Over the previous 90 days, GSK's stock had 1 upgrade and 1 downgrade by analysts.

GSK has been rated by research analysts at Weiss Ratings in the past 90 days.

Analysts like GSK less than other "medical" companies. The consensus rating for GSK is Reduce while the average consensus rating for "medical" companies is Hold. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With GSK Recommendations

This page (NYSE:GSK) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Stock Forecast & Price Target

GSK - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

GSK Analyst Ratings Over Time

GSK Analyst Recommendations By Month

GSK Price Targets by Month

GSK Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy GSK Stock? GSK Pros and Cons Explained

GSK
Bull Case

GSK
Bear Case

GSK Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With GSK Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GSK (GSK) Stock Forecast & Price Target

GSK - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

GSK Analyst Ratings Over Time

GSK Analyst Recommendations By Month

GSK Price Targets by Month

GSK Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy GSK Stock? GSK Pros and Cons Explained

GSK Bull Case

GSK Bear Case

GSK Forecast - Frequently Asked Questions

What is GSK's forecast for 2026?

Should I buy or sell GSK stock right now?

Does GSK's stock price have much upside?

Has GSK been upgraded or downgraded by Wall Street analysts recently?

What analysts cover GSK?

Do Wall Street analysts like GSK more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With GSK Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

GSK
Bull Case

GSK
Bear Case